Related Experiment Videos
Trials in women
1The Carlo Besta Neurological Institute, Via Celoria 11, 1-20133, Milan, Italy. dbattino@istituto-besta.it
Abstract:
Women of childbearing age have been viewed as a 'vulnerable population' and have been systematically excluded from early clinical trials. A change in attitude and policies occurred in the last decade, with a consequent increase of women participating in clinical trials. The implications are increasing respect for the woman's capacity to make her own risk-benefit choices, early evaluation of patients that represent the ultimate user of a drug and equal opportunities for women to benefit from the therapeutic potential of new drugs. Drug trials should be designed to identify sex-related effects and to analyse the efficacy and tolerability of antiepileptic drugs (AEDs) by gender. Further aspects should be considered, including changes in response in relation to the menstrual cycle and over the various stages of reproductive life; interactions between hormonal therapies and AEDs; the effect of AEDs on reproductive function and possible consequences of prenatal exposure to AEDs. These considerations become even more critical when pregnant and lactating women are considered, since any risk for the offspring is unacceptable unless drug administration is likely to have major medical benefits for the mother.
Insights
Women are increasingly included in clinical trials, ensuring new drugs benefit everyone. Research must now focus on sex-specific effects of antiepileptic drugs (AEDs) for women of all reproductive stages.
Area of Science:
- Pharmacology
- Clinical Trials
- Women's Health
Background:
- Historically, women of childbearing age were excluded from clinical trials, often deemed a 'vulnerable population'.
- Recent policy shifts have led to increased female participation in clinical trials.
- This change promotes respect for women's autonomy in healthcare decisions and ensures equitable access to new medications.
Purpose of the Study:
- To advocate for the inclusion of women in clinical trials.
- To emphasize the need for gender-specific analysis of drug efficacy and tolerability, particularly for antiepileptic drugs (AEDs).
- To highlight critical considerations for women across reproductive stages, including pregnant and lactating individuals.
Main Methods:
- Review of historical exclusion and recent policy changes regarding women in clinical trials.
- Discussion of the implications of increased female participation.
- Identification of key areas for future research in sex-specific drug evaluation.
Main Results:
- Increased participation of women in clinical trials respects their decision-making capacity.
- Early evaluation of drugs in the ultimate user population (women) is now possible.
- Equal opportunities for women to benefit from therapeutic advancements are being established.
Conclusions:
- Clinical trials must be designed to identify sex-related effects of drugs, especially antiepileptic drugs (AEDs).
- Research should address menstrual cycle, reproductive stages, hormonal therapy interactions, reproductive function, and prenatal exposure effects.
- Special attention is crucial for pregnant and lactating women, prioritizing offspring safety unless maternal benefits are substantial.